Xwpharma

Xwpharma company information, Employees & Contact Information

Updated June 2026

Quick answer

Xwpharma is a Biotechnology company. It has approximately 19 employees on record. Contact data was last refreshed in June 2026. Find Xwpharma's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

We are a global biotech with a pipeline of internally discovered novel small molecule drug candidates focused on neurological and neuropsychiatric disorders. *PLEASE NOTE, XW is NOT currently hiring. Someone is fraudulently offering work in our name.
Looking for a particular Xwpharma employee's phone or email?

Xwpharma Questions

News

Avadel Pharmaceuticals and XWPharma Enter Exclusive License Agreement for Valiloxybate, a Novel Once-at-Bedtime Oxybate for Sleep Disorders - Quiver Quantitative

Avadel Pharmaceuticals and XWPharma Enter Exclusive License Agreement for Valiloxybate, a Novel Once-at-Bedtime Oxybate for Sleep Disorders Quiver Quantitative

Salt-Free Sleep Drug Deal: Avadel Pharma Expands Portfolio with $20M Valiloxybate License for Narcolepsy - Stock Titan

Salt-Free Sleep Drug Deal: Avadel Pharma Expands Portfolio with $20M Valiloxybate License for Narcolepsy Stock Titan

Avadel & XWPharma Unveil $2B+ Deal for Sleep Disorder Drug - NAVLIN DAILY

Avadel & XWPharma Unveil $2B+ Deal for Sleep Disorder Drug NAVLIN DAILY

Avadel Partners with XWPharma to Commercialize Sleep Medication - Pharmaceutical Executive

Avadel Partners with XWPharma to Commercialize Sleep Medication Pharmaceutical Executive

Avadel licenses once-at-bedtime oxybate therapy from XWPharma - Investing.com

Avadel licenses once-at-bedtime oxybate therapy from XWPharma Investing.com

Avadel secures rights to develop valiloxybate globally - Pharmaceutical Technology

Avadel secures rights to develop valiloxybate globally Pharmaceutical Technology

The Once-Nightly, Salt-Free, Artificial Sweetener-Free Oxybate in the Works for Narcolepsy, IH - Sleep Review

The Once-Nightly, Salt-Free, Artificial Sweetener-Free Oxybate in the Works for Narcolepsy, IH Sleep Review

Addressing unmet needs in treating a wide range of neurological disorders - Nature

Addressing unmet needs in treating a wide range of neurological disorders Nature

XWPharma takes in $40m series C round - - Global Venturing

XWPharma takes in $40m series C round - Global Venturing

Top Xwpharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant